ROBERTO COSTA

(Fonte: Lattes)
Índice h a partir de 2011
14
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

Colaboração internacional: Austrália ×

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • article 109 Citação(ões) na Scopus
    European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
    (2020) BLOMSTROM-LUNDQVIST, Carina; TRAYKOV, Vassil; ERBA, Paola Anna; BURRI, Haran; NIELSEN, Jens Cosedis; BONGIORNI, Maria Grazia; POOLE, Jeanne; BORIANI, Giuseppe; COSTA, Roberto; DEHARO, Jean-Claude; EPSTEIN, Laurence M.; SAGHY, Laszlo; SNYGG-MARTIN, Ulrika; STARCK, Christoph; TASCINI, Carlo; STRATHMORE, Neil
    Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are potentially lifesaving treatments for a number of cardiac conditions but are not without risk. Most concerning is the risk of a cardiac implantable electronic device (CIED) infection, which is associated with significant morbidity, increased hospitalizations, reduced survival, and increased health care costs. Recommended preventive strategies such as administration of intravenous antibiotics before implantation are well-recognized. Uncertainties have remained about the role of various preventive, diagnostic, and treatment measures such as skin antiseptics, pocket antibiotic solutions, antibacterial envelopes, prolonged antibiotics post-implantation, and others. When compared with previous guidelines or consensus statements, the present consensus document gives guidance on the use of novel device alternatives, novel oral anticoagulants, antibacterial envelopes, prolonged antibiotics post-implantation, as well as definitions on minimum quality requirements for centres and operators and volumes. The recognition that an international consensus document focused on management of CIED infections is lacking, the dissemination of results from new important randomized trials focusing on prevention of CIED infections, and observed divergences in managing device-related infections as found in an European Heart Rhythm Association worldwide survey, provided a strong incentive for a Novel 2019 International State-of-the-art Consensus document on risk assessment, prevention, diagnosis, and treatment of CIED infections.
  • article 237 Citação(ões) na Scopus
    European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
    (2020) BLOMSTROM-LUNDQVIST, Carina; TRAYKOV, Vassil; ERBA, Paola Anna; BURRI, Haran; NIELSEN, Jens Cosedis; BONGIORNI, Maria Grazia; POOLE, Jeanne; BORIANI, Giuseppe; COSTA, Roberto; DEHARO, Jean-Claude; EPSTEIN, Laurence M.; SAGHY, Laszlo; SNYGG-MARTIN, Ulrika; STARCK, Christoph; TASCINI, Carlo; STRATHMORE, Neil
    Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are potentially life-saving treatments for a number of cardiac conditions, but are not without risk. Most concerning is the risk of a cardiac implantable electronic device (CIED) infection, which is associated with significant morbidity, increased hospitalizations, reduced survival, and increased healthcare costs. Recommended preventive strategies such as administration of intravenous antibiotics before implantation are well recognized. Uncertainties have remained about the role of various preventive, diagnostic, and treatment measures such as skin antiseptics, pocket antibiotic solutions, anti-bacterial envelopes, prolonged antibiotics post-implantation, and others. Guidance on whether to use novel device alternatives expected to be less prone to infections and novel oral anticoagulants is also limited, as are definitions on minimum quality requirements for centres and operators and volumes. Moreover, an international consensus document on management of CIED infections is lacking. The recognition of these issues, the dissemination of results from important randomized trials focusing on prevention of CIED infections, and observed divergences in managing device-related infections as found in an European Heart Rhythm Association worldwide survey, provided a strong incentive for a 2019 International State-of-the-art Consensus document on risk assessment, prevention, diagnosis, and treatment of CIED infections.
  • article 56 Citação(ões) na Scopus
    Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association
    (2019) TRAYKOV, Vassil; BONGIORNI, Maria Grazia; BORIANI, Giuseppe; BURRI, Haran; COSTA, Roberto; DAGRES, Nikolaos; DEHARO, Jean-Claude; EPSTEIN, Laurence M.; ERBA, Paola Anna; SNYGG-MARTIN, Ulrika; NIELSEN, Jens Cosedis; POOLE, Jeanne E.; SAGHY, Laszlo; STARCK, Christoph; STRATHMORE, Neil; BLOMSTROM-LUNDQVIST, Carina
    Aims Cardiac implantable electronic device (CIED) infection rates are increasing. Worldwide compliance and disparities to published guidelines for the prevention, diagnosis and management of these conditions are not well elucidated. The purpose of this survey, therefore, was to clarify these issues through an inquiry to arrhythmia-related associations and societies worldwide. Methods and results A questionnaire comprising 15 questions related to CIED infections was distributed among members of seven arrhythmia societies worldwide. A total of 234 centres in 62 countries reported implantation rates of which 159 (68.0%) performed more than 200 device implantations per year and 14 (6.0%) performed fewer than 50 implantations per year. The reported rates of CIED infections for 2017 were <= 2% in 78.7% of the centres, while the infection rates exceeded 5% in 7.8% of the centres. Preventive measures for CIED infection differed from published recommendations and varied among different regions mainly in terms of pocket irrigation and administering postoperative antimicrobial therapy the use of which was reported by 39.9% and 44% of the respondents, respectively. Antibacterial envelopes were used by 37.7% of the respondents in selected circumstances. In terms of pocket infection management, 62% of the respondents applied complete system removal as an initial step. Diagnostic pocket needle aspiration and pocket surgical debridement were reported by 15.8% and 11.8% of centres, respectively. Conclusion Clinical practices for prevention and management of CIED do not fully comply with current recommendations and demonstrate considerable regional disparities. Further education and programmes for improved implementation of guidelines are mandatory.
  • article 30 Citação(ões) na Scopus
    European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
    (2020) BLOMSTROM-LUNDQVIST, Carina; TRAYKOV, Vassil; ERBA, Paola Anna; BURRI, Haran; NIELSEN, Jens Cosedis; BONGIORNI, Maria Grazia; POOLE, Jeanne; BORIANI, Giuseppe; COSTA, Roberto; DEHARO, Jean-Claude; EPSTEIN, Laurence M.; SAGHY, Laszlo; SNYGG-MARTIN, Ulrika; STARCK, Christoph; TASCINI, Carlo; STRATHMORE, Neil
    Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are potentially life-saving treatments for a number of cardiac conditions, but are not without risk. Most concerning is the risk of a cardiac implantable electronic device (CIED) infection, which is associated with significant morbidity, increased hospitalizations, reduced survival, and increased healthcare costs. Recommended preventive strategies such as administration of intravenous antibiotics before implantation are well recognized. Uncertainties have remained about the role of various preventive, diagnostic, and treatment measures such as skin antiseptics, pocket antibiotic solutions, anti-bacterial envelopes, prolonged antibiotics post-implantation, and others. Guidance on whether to use novel device alternatives expected to be less prone to infections and novel oral anticoagulants is also limited, as are definitions on minimum quality requirements for centres and operators and volumes. Moreover, an international consensus document on management of CIED infections is lacking. The recognition of these issues, the dissemination of results from important randomized trials focusing on prevention of CIED infections, and observed divergences in managing device-related infections as found in an European Heart Rhythm Association worldwide survey, provided a strong incentive for a 2019 International State-of-the-art Consensus document on risk assessment, prevention, diagnosis, and treatment of CIED infections.
  • article 263 Citação(ões) na Scopus
    2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS
    (2018) BONGIORNI, Maria G.; BURRI, Haran; DEHARO, Jean C.; STARCK, Christoph; KENNERGREN, Charles; SAGHY, Laszlo; RAO, Archana; TASCINI, Carlo; LEVER, Nigel; KUTARSKI, Andrzej; LOZANO, Ignacio Fernandez; STRATHMORE, Neil; COSTA, Roberto; EPSTEIN, Laurence; LOVE, Charles; BLOMSTROM-LUNDQVIST, Carina; FAUCHIER, Laurent; DEFAYE, Pascal; ARNAR, David O.; KLUG, Didier; BOVEDA, Serge; NIELSEN, Jens Cosedis; BORIANI, Giuseppe; ZHANG, Shu; MARTIN, Andrew Paul; PRUTKIN, Jordan M.; ZULOAGA, Claudio de